Aug 16, 2026 · 50 min
GLP-1 drugs reshape appetite science and metabolic medicine
Why Your Brain Thinks You're Full (Even When You're Not)
The episode connects a decades-long chain of metabolic research to drugs that may alter hunger, compulsive behavior, food economics, and biological risk.
- 1GLP-1 drugs coordinate insulin, glucagon, digestion, and brain appetite pathways rather than simply suppressing hunger.
- 2A stable peptide from Gila monster venom helped transform fragile GLP-1 biology into longer-lasting medicines.
- 3Appetite control could challenge ultra-processed food incentives while raising unresolved questions about compulsion, culture, and safety.
Don't miss
The discovery that Gila monster venom contained a durable GLP-1-like peptide shows how an unexpected biological clue helped reshape metabolic medicine.
The brief
Hannah Fry and Michael Stevens begin with the body’s narrow blood-sugar range, then show why insulin, glucagon, and digestion form a tightly linked control system.
The key discovery is GLP-1: a gut signal that boosts insulin when glucose is high, lowers glucagon, slows stomach emptying, and reaches appetite pathways in the brain.
Early GLP-1 treatments failed because the peptide broke down quickly and caused severe nausea. A more durable analogue from Gila monster venom changed the trajectory.
The hosts connect appetite-suppressing drugs to ultra-processed food design and commercial incentives, while weighing possible effects on alcohol, smoking, gambling, and other compulsions.
The episode closes on a wider tension: AI may accelerate safer, more effective medicines, but the same biological design tools could intensify new risks.